Is atropine the next step for myopia?
The MHRA recently approved the use of low concentration atropine drops for childhood myopia in the UK. In this video, Professor Nicola Logan discusses the evidence regarding clinical efficacy, safety profiles and tolerability, rebound effect, and combination therapy with optical interventions. Participants will gain insights into how these interventions can be integrated into everyday practice, and future directions for the next steps in myopia management in the UK. After watching the video, you will be directed to a closed discussion group on LinkedIn, to interact with your peers
To view this content, please log in.
Not a member or subscriber? Join AOP today for access to a whole range of benefits, or subscribe to OT for immediate access to our premium content.
